BRAF and non-small cell lung carcinoma: Current case reports suggest that patients with advanced NSCLC who develop resistance to EGFR-TKI therapy with a concurrent BRAF V600 mutation may benefit from a dual-targeted treatment combined with EGFR-TKI.